Tyra Biosciences, Inc. (TYRA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 24.62M USD | Liabilities, Current |
| Cash and equivalents | 73.83M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $24.62M | $73.83M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $19.26M | $84.95M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $18.09M | $77.39M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $15.88M | $61.95M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.77M | $98.49M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $14.25M | $100.72M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.59M | $91.97M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $12.37M | $103.89M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $10.38M | $99.49M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.72M | $254.37M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $15.33M | $58.01M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $10.15M | $215.65M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.41M | $232.41M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $3.68M | $241.70M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.70M | $251.21M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.49M | $263.21M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.46M | $275.11M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $4.90M | $292.50M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.62M | $302.18M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $4.77M | $312.82M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $135.20M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $140.64M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.86M | $15.22M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $18.07M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |